ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v9i5.457ppharm-290Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL ARTICLESРОЛЬ N-КОНЦЕВОГО ФРАГМЕНТА МОЗГОВОГО НАТРИЙУРЕТИЧЕСКОГО ПЕПТИДА В ДИАГНОСТИКЕ НЕКОМПАКТНОГО МИОКАРДА У ДЕТЕЙN-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN DIAGNOSTICS OF NON-COMPACTED MYOCARDIUM IN CHILDRENАрхиповаЕ. Н.ArkhipovaE. N.
аспирант кардиологического отделения ФГБУ «Научный центр здоровья детей» РАМН
neonatepearl@yandex.ruСильноваИ. В.Sil’novaI. V.neonatepearl@yandex.ruБасаргинаЕ. Н.BasarginaE. N.neonatepearl@yandex.ruДворяковскийИ. В.DvoryakovskiiI. V.neonatepearl@yandex.ruСугакА. Б.SugakA. B.neonatepearl@yandex.ruМаянскийН. А.MayanskiiN. A.neonatepearl@yandex.ruУмароваМ. К.UmarovaM. K.neonatepearl@yandex.ruНаучный центр здоровья детей РАМН, Москва, Российская ФедерацияРоссияScientific Center of Children’s Health of RAMS, Moscow, Russian FederationRussian Federation20120510201295Педиатрическая фармакология6569Copyright © Архипова Е.Н., Сильнова И.В., Басаргина Е.Н., Дворяковский И.В., Сугак А.Б., Маянский Н.А., Умарова М.К., 20122012Архипова Е.Н., Сильнова И.В., Басаргина Е.Н., Дворяковский И.В., Сугак А.Б., Маянский Н.А., Умарова М.К.Arkhipova E.N., Sil’nova I.V., Basargina E.N., Dvoryakovskii I.V., Sugak A.B., Mayanskii N.A., Umarova M.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/290некомпактный миокардNT-proBNPсердечная недостаточностьдиагностикадетиnon-compacted myocardiumNT-proBNPcardiac insufficiencydiagnosticschildrenReferencesSanchez-Quintana D., Garcia-Martinez V., Climent V., Hurle J. M. Morphological changes in the normal pattern of ventricular myoarchitecture in the developing human heart. Anat. Rec. 1995; 243: 483–495.Sanchez-Quintana D., Garcia-Martinez V., Climent V., Hurle J. M. Morphological changes in the normal pattern of ventricular myoarchitecture in the developing human heart. Anat. Rec. 1995; 243: 483–495.Sedmera D., Pexieder T., Vuillemin M. et al. Developmental patterning of the myocardium. Anat. Rec. 2000; 258: 319–337. 3. Srivastava D., Olson E. N. A genetic blueprint for cardiac development. Nature. 2000; 407: 221–226.Sedmera D., Pexieder T., Vuillemin M. et al. Developmental patterning of the myocardium. Anat. Rec. 2000; 258: 319–337. 3. Srivastava D., Olson E. N. A genetic blueprint for cardiac development. Nature. 2000; 407: 221–226.Nugent A. W., Daubeney P. E., Chondros P. et al. National Australian childhood cardiomyopathy study: the epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003; 348: 1639–1646.Nugent A. W., Daubeney P. E., Chondros P. et al. National Australian childhood cardiomyopathy study: the epidemiology of childhood cardiomyopathy in Australia. N Engl J Med. 2003; 348: 1639–1646.Sasse-Klaassen S., Gerull B., Oechslin E. et al. Isolated noncompaction of the left ventricular myocardium in the adult is an autosomal dominant disorder in the majority of patients. Am J Med Genet. 2003; 119A: 162–167.Sasse-Klaassen S., Gerull B., Oechslin E. et al. Isolated noncompaction of the left ventricular myocardium in the adult is an autosomal dominant disorder in the majority of patients. Am J Med Genet. 2003; 119A: 162–167.Junga G., Kneifel S., Von Smekal A. et al. Myocardial ischaemia in children with isolated ventricular non-compaction. Eur Heart J. 1999; 20 (12): 910–916.Junga G., Kneifel S., Von Smekal A. et al. Myocardial ischaemia in children with isolated ventricular non-compaction. Eur Heart J. 1999; 20 (12): 910–916.Jenni R., Wyss C., Oechslin E., Kaufmann P. Isolated ventricular noncompaction is associated with coronary microcirculatory dysfunction. J Am Coll Cardiol. 2002; 39: 450–454.Jenni R., Wyss C., Oechslin E., Kaufmann P. Isolated ventricular noncompaction is associated with coronary microcirculatory dysfunction. J Am Coll Cardiol. 2002; 39: 450–454.Alsaileek A. A., Syed I., Seward J. B., Julsrud P. Myocardial fibrosis of left ventricle: magnetic resonance imaging in noncompaction. J Magn Reson Imaging. 2008; 27 (3): 621–624.Alsaileek A. A., Syed I., Seward J. B., Julsrud P. Myocardial fibrosis of left ventricle: magnetic resonance imaging in noncompaction. J Magn Reson Imaging. 2008; 27 (3): 621–624.Finsterer J., Stollberger C., Feichtinger H. Histological appearance of left ventricular hypertrabeculation/noncompaction. Cardiology. 2002; 98: 162–164.Finsterer J., Stollberger C., Feichtinger H. Histological appearance of left ventricular hypertrabeculation/noncompaction. Cardiology. 2002; 98: 162–164.Freedom R., Yoo S-J., Perrin D. et al. The morphological spectrum of ventricular noncompaction. Cardiol Young. 2005; 15: 345–364.Freedom R., Yoo S-J., Perrin D. et al. The morphological spectrum of ventricular noncompaction. Cardiol Young. 2005; 15: 345–364.Ross R. Grading the severity of congestive heart failure in infants. Pediatr Cardiol. 1992; 13: 72–75.Ross R. Grading the severity of congestive heart failure in infants. Pediatr Cardiol. 1992; 13: 72–75.Toyono M., Kondo C., Nakajima Y. et al. Effects of carvedilol on left ventricular function, mass, and scintigraphic findings in isolated left ventricular non-compaction. Heart. 2001; 86: 4–6.Toyono M., Kondo C., Nakajima Y. et al. Effects of carvedilol on left ventricular function, mass, and scintigraphic findings in isolated left ventricular non-compaction. Heart. 2001; 86: 4–6.Braunwald E. The management of heart failure: the past, the present, and the future. Circ Heart Fail. 2008; 1: 58–62.Braunwald E. The management of heart failure: the past, the present, and the future. Circ Heart Fail. 2008; 1: 58–62.Katz A. M. Heart failure: pathophysiology, molecular biology, and clinical management. Philadelphia: Lippincott Williams & Wilkins. 2000.Katz A. M. Heart failure: pathophysiology, molecular biology, and clinical management. Philadelphia: Lippincott Williams & Wilkins. 2000.Konstam M. A. «Systolic and diastolic dysfunction» in heart failure? Time for a new paradigm. J Card Fail. 2003; 9: 1–3.Konstam M. A. «Systolic and diastolic dysfunction» in heart failure? Time for a new paradigm. J Card Fail. 2003; 9: 1–3.Packer M. How should physician view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol. 1993; 71: 3–11.Packer M. How should physician view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol. 1993; 71: 3–11.Nakao K., Itoh H., Saito Y. et al. The natriuretic peptide family. Curr Opin Nephrol Hypertens. 1996; 5: 4–11.Nakao K., Itoh H., Saito Y. et al. The natriuretic peptide family. Curr Opin Nephrol Hypertens. 1996; 5: 4–11.Levin E. R., Gardner D. G., Samson W. K. Natriuretic peptides. N Engl J Med. 1998; 339: 321–328.Levin E. R., Gardner D. G., Samson W. K. Natriuretic peptides. N Engl J Med. 1998; 339: 321–328.Johns M. C., Stephenson C. Amino-terminal pro-B-type natriuretic peptide testing in neonatal and pediatric patients. Am J Cardiol. 2008; 101: 76–81.Johns M. C., Stephenson C. Amino-terminal pro-B-type natriuretic peptide testing in neonatal and pediatric patients. Am J Cardiol. 2008; 101: 76–81.Davis G. K., Bamforth F., Sarpal A. B-type natriuretic peptide in pediatrics. Clin Biochem. 2006; 39: 600–605.Davis G. K., Bamforth F., Sarpal A. B-type natriuretic peptide in pediatrics. Clin Biochem. 2006; 39: 600–605.Mir T. S., Marohn S., Laer S. et al. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics. 2002; 110 (6): 76.Mir T. S., Marohn S., Laer S. et al. Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics. 2002; 110 (6): 76.Bolger A. P., Sharma R., Li W. et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation. 2002; 106: 92–99.Bolger A. P., Sharma R., Li W. et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation. 2002; 106: 92–99.Ohuchi H., Ohashi H., Park J. et al. Abnormal postexercise cardio: vascular recovery and its determinants in patients after right ventricular outflow tract reconstruction. Circulation. 2002; 106: 2819–2826.Ohuchi H., Ohashi H., Park J. et al. Abnormal postexercise cardio: vascular recovery and its determinants in patients after right ventricular outflow tract reconstruction. Circulation. 2002; 106: 2819–2826.Price J. F., Thomas A. K., Grenier M. et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation. 2006; 114: 1063–1069.Price J. F., Thomas A. K., Grenier M. et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation. 2006; 114: 1063–1069.Архипова Е. Н., Родионова Т. В., Басаргина Е. Н., Маянский Н. А. Закономерности изменения содержания NT-proBNP в крови и их диагностическая значимость у детей с хронической сердечной недостаточностью. Лабораторная диагностика в педиатрии. 2012; 4 (3): 11–16.Архипова Е. Н., Родионова Т. В., Басаргина Е. Н., Маянский Н. А. Закономерности изменения содержания NT-proBNP в крови и их диагностическая значимость у детей с хронической сердечной недостаточностью. Лабораторная диагностика в педиатрии. 2012; 4 (3): 11–16.
The authors declare that there are no conflicts of interest present.